- Home
- ADXN
as 11-15-2024 9:40am EST
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
| Founded: | 2002 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 11.3M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 56.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.00 - $27.90 | Next Earning Date: | 11-22-2024 |
| Revenue: | $960,641 | Revenue Growth: | -59.82% |
| Revenue Growth (this year): | -25.69% | Revenue Growth (next year): | -37.50% |
Latest Addex Therapeutics Ltd News
ADXN Breaking Stock News: Dive into ADXN Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
GlobeNewswire
2 months ago
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
GlobeNewswire
2 months ago
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
GlobeNewswire
2 months ago
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
3 months ago
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
GlobeNewswire
4 months ago
Addex’s Partner Discontinues ADX71149 development in Epilepsy
GlobeNewswire
4 months ago
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
GlobeNewswire
4 months ago
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
Compare ADXN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADXN Addex Therapeutics Ltd - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.